CD274 and non-small cell lung carcinoma: ICI therapy was first shown to have benefits in the stage IV NSCLC in the second-line with studies comparing nivolumab and pembrolizumab, programmed death 1 (PD-1) inhibitors along with atezolizumab, a PD-L1 inhibitor, with docetaxel and showing significant overall response rate (ORR) and OS benefit [27–30].